ZFIN Fish: gz15Tg; gz32Tg

ZFIN ID: ZDB-FISH-151105-26

ZFIN ID: ZDB-FISH-151105-26

Fish name:	gz15Tg; gz32Tg
Genotype:	gz15Tg; gz32Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by gz15Tg; gz32Tg

Human Disease	Conditions	Citations
hepatocellular carcinoma	chemical treatment by environment: doxycycline HCl	Li et al., 2019

GENE EXPRESSION
Gene expression in gz15Tg; gz32Tg

RNA expression No data available

Protein expression

Antibody	Antigen Genes	Structure	Conditions	Figures
Ab1-casp3		liver	chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor	Fig. 5 from Yan et al., 2015
Ab5-pcna		liver	chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor	Fig. 5 from Yan et al., 2015

Reporter gene expression

Expressed Gene	Structure	Conditions	Figures
DsRed	liver	chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
EGFP	liver	chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor	Fig. 5 from Yan et al., 2015

PHENOTYPE
Phenotype in gz15Tg; gz32Tg

Phenotype	Conditions	Figures
hepatocyte apoptotic process increased process quality, abnormal	chemical treatment: doxycycline monohydrate	Fig. 5 from Yan et al., 2015
hepatocyte apoptotic process increased process quality, abnormal	chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor	Fig. 5 from Yan et al., 2015
hepatocyte cell population proliferation increased process quality, abnormal	chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate	Fig. 5 from Yan et al., 2015
hepatocyte cell population proliferation increased process quality, abnormal	chemical treatment: doxycycline monohydrate	Fig. 5 from Yan et al., 2015
liver DsRed expression amount, ameliorated	chemical treatment by environment: nanoparticle, chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
liver DsRed expression amount, ameliorated	chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
liver hyperplastic, abnormal	chemical treatment: doxycycline monohydrate, chemical treatment: NF-kappaB inhibitor	Fig. 6 from Yan et al., 2015
liver DsRed expression increased amount, abnormal	chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
liver increased volume, abnormal	chemical treatment: doxycycline monohydrate	Fig. 2 from Chew et al., 2014
liver neoplastic, abnormal	chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
liver neoplastic, ameliorated	chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
liver neoplastic, ameliorated	chemical treatment by environment: nanoparticle, chemical treatment by environment: doxorubicin, chemical treatment by environment: doxycycline HCl	Fig. 6 from Li et al., 2019
liver hepatocellular carcinoma increased occurrence, abnormal	chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate	Fig. 6 from Yan et al., 2015
liver hepatocellular carcinoma increased occurrence, abnormal	chemical treatment: doxycycline monohydrate	Fig. 6 from Yan et al., 2015

CITATIONS (3)